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to mammography screening in women aged 40
to 49 in the United Kingdom
Necdet B Gunsoy1*, Montserrat Garcia-Closas1,2 and Sue M Moss3
Abstract
Introduction: Overdiagnosis of breast cancer due to mammography screening, defined as the diagnosis of screen-
detected cancers that would not have presented clinically in a women’s lifetime in the absence of screening, has
emerged as a highly contentious issue, as harm caused may question the benefit of mammographic screening.
Most studies included women over 50 years old and little information is available for younger women.
Methods: We estimated the overdiagnosis of breast cancer due to screening in women aged 40 to 49 years using
data from a randomised trial of annual mammographic screening starting at age 40 conducted in the UK. A six-
state Markov model was constructed to estimate the sensitivity of mammography for invasive and in situ breast
cancer and the screen-detectable mean sojourn time for non-progressive in situ, progressive in situ, and invasive
breast cancer. Then, a 10-state simulation model of cancer progression, screening, and death, was developed to
estimate overdiagnosis attributable to screening.
Results: The sensitivity of mammography for invasive and in situ breast cancers was 90% (95% CI, 72 to 99) and
82% (43 to 99), respectively. The screen-detectable mean sojourn time of preclinical non-progressive and
progressive in situ cancers was 1.3 (0.4 to 3.4) and 0.11 (0.05 to 0.19) years, respectively, and 0.8 years (0.6 to 1.2)
for preclinical invasive breast cancer. The proportion of screen-detected in situ cancers that were non-progressive
was 55% (25 to 77) for the first and 40% (22 to 60) for subsequent screens. In our main analysis, overdiagnosis was
estimated as 0.7% of screen-detected cancers. A sensitivity analysis, covering a wide range of alternative scenarios,
yielded a range of 0.5% to 2.9%.
Conclusion: Although a high proportion of screen-detected in situ cancers were non-progressive, a majority of
these would have presented clinically in the absence of screening. The extent of overdiagnosis due to screening in
women aged 40 to 49 was small. Results also suggest annual screening is most suitable for women aged 40 to 49
in the United Kingdom due to short cancer sojourn times.
Introduction
Since the introduction of mammography screening in
many countries, a substantial increase in the incidence of
breast cancers has been observed, raising concern about
the potential for overdiagnosis of breast cancer due to
screening. However, no consensus has been reached on
the extent of such overdiagnosis. An overdiagnosed
breast cancer is defined as one which is screen-detected,
and would never have presented clinically in a woman’s
lifetime in the absence of screening [1]. In addition to
overdiagnosis and consequent overtreatment, screening
results in additional years lived with breast cancer due to
the advancement of time of diagnosis. Estimates of over-
diagnosis in previous studies vary considerably. Compari-
sons of expected breast cancer incidence extrapolated
from rates before the introduction of screening with that
observed after have resulted in estimates of overdiagnosis
ranging from 4% [2] to 52% [3] of all diagnosed breast
cancers. Variations between estimates reflect the metho-
dological challenges faced when estimating overdiagnosis.
A drop in breast cancer incidence is observed in the age
group immediately above that invited for screening due
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to the advancement of diagnosis of these cases by screen-
ing. Studies that do not account for this compensatory
drop tend to have a higher estimate of overdiagnosis.
Estimates will also vary depending on whether or not in
situ cancers are included [1,4].
Simulation modelling is a popular tool for estimating
the extent of overdiagnosis due to screening; it requires
estimates of the mean duration of pre clinical cancer
states (mean sojourn time), the screening test sensitivity
(STS), and the background incidence of breast cancer in
the absence of screening. De Koning et al. applied this
approach to Dutch screening data for women aged 50
to 74, and estimated that 3% of all cancers and 8% of
screen-detected cancers were overdiagnosed [5].
Most estimates of overdiagnosis are based on data for
women aged 50 years and over, as younger women are
currently not eligible for screening in most countries.
The extension of the age range of screening pro-
grammes to include younger women is under debate,
but little is known on the extent of overdiagnosis due to
screening in these women. Also, evidence suggest that
younger women tend to have breast cancers that pro-
gress faster and lower mammography STS, mostly due
to higher breast density, than older women [6-9], which
may be favourable with regards to overdiagnosis.
In this study, we model data from a trial of mammo-
graphic screening for breast cancer starting at age 40
(Age trial) conducted in the UK, using data collected
from the start of the trial in 1991 until 31st December
2010, in order to estimate, in women aged 40 to 49:
1. the STS of mammography for invasive and in situ
breast cancers, that is the probability of a mammo-
graphic screen detecting a cancer that is in the pre-
clinical state,
2. the mean sojourn time (MST), that is the mean
duration, in years, for a cancer from first becoming
detectable by screening to clinical diagnosis, of the
screen-detectable preclinical breast cancer states:
progressive in situ, non-progressive in situ, and
invasive,
3. the proportion of screen-detected in situ cancers
that are non-progressive,
4. the proportion of breast cancers diagnosed that
would not have presented clinically in the absence of
screening after accounting for a compensatory drop
in incidence.
Materials and methods
Data
Details of the Age trial are given elsewhere [10]. In sum-
mary, a randomised controlled trial was designed to
assess the effectiveness of annual screening by mammo-
graphy in women from age 40 onwards in the UK. The
trial comprised of an intervention arm of 53,890 women
assigned to annual screening invitation and a control
arm of 106,971 women not offered screening. Recruit-
ment began in 1991 and the trial included 23 centres.
Women were invited each year, except for those who
specified that they did not wish to participate in the
trial. Two-view mammography was performed on the
first attendance to screening. The following screens
were single view unless otherwise indicated. All diag-
nosed breast cancers, including interval, screen-detected,
and those in the control arm, were recorded and sub-
mitted to a pathologic review.
Women with diagnosed breast cancer at entry to the
trial were excluded from this analysis. Out of the 53,890
women assigned to the intervention arm, 36,348
attended the first screen and were eligible for analysis.
For each following screen, women were included only if
they attended all previous screening rounds. Only
screening episodes recorded from ages 40 to 49 years as
part of the trial were considered, and the analysis was
limited to the first eight screening invitations since few
women received more than this number. The exact date
of each screen and of any breast cancer diagnosis was
known for each woman. Interval cancers were defined
as cancers diagnosed up to 12 months after a negative
routine screen, and time since the previous negative
screen was calculated in months. In all eight screening
rounds, a total of 194 screen-detected, and 122 interval
cancers were recorded. The numbers of women
screened, and of screen-detected and interval cancers in
each screening round are presented for in situ and inva-
sive cancers in Table 1.
The Age trial is registered as an International Stan-
dard Randomised Controlled Trial, number 24647151.
Ethical approval was obtained for the trial from London
MREC (MREC/98/2/40), and NGIB (formerly PIAG)
approval (PIAG 3-07(h)/2002) was obtained for the use
of identifiable patient information.
Statistical methods
We constructed two Markov models to estimate the
extent of overdiagnosis (Figure 1): one to estimate
screening parameters based on the Age trial data (para-
meter estimation model), and one to estimate overdiag-
nosis based on parameter estimates from the first model
(overdiagnosis model).
Parameter estimation model
We constructed a six-state Markov model similar to that
in a previous study [11]; states included were healthy,
screen-detectable non-progressive in situ (NPIS), clini-
cally diagnosed non-progressive in situ (CIS), screen-
detectable progressive in situ (PIS), screen-detectable
preclinical invasive breast cancer (PIBC), and clinically
diagnosed invasive breast cancer (CIBC).
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Several important assumptions were made on the nat-
ural history of breast cancer in order to simplify the
model specification. First, we assumed that there were
two types of in situ lesions: one that would progress into
invasive cancer, and another that would never progress
into invasive cancer, but could become clinically detected
in the absence of screening. Thus, PIS would not be diag-
nosed in the absence of screening and would eventually
progress into PIBC before becoming clinically diagnosed.
Also, in situ cancers detected at screening would be
either from PIS or NPIS, whereas those observed in the
screening interval or in the absence of screening would
be exclusively from NPIS. Second, we assumed that all
PIBC have a mandatory PIS precursor. Finally, we
assumed that preclinical cancers could not regress, but
only remain in their current state or progress.
Table 1 Cancer detection by screening round in a trial of annual mammographic screening starting age 40, UK.
Screening round Women screened1 Screen-detected
cancers
ICs2 in the first 12
months
Mean age (years) Mean screening interval (years)
INV3 IS4 INV3 IS4
1 36 348 31 6 7 2 40.5 -
2 30 779 20 3 17 2 41.6 1.1
3 27 083 16 3 17 0 42.6 1.1
4 24 188 15 5 17 1 43.7 1.1
5 21 107 16 4 10 0 44.7 1.0
6 18 603 13 7 16 1 45.6 1.0
7 17 193 19 9 18 1 46.6 1.0
8 13 998 21 6 11 2 47.5 0.9
Total 189 299 151 43 113 9 43.4
1Only includes women screened at all previous rounds; 2interval cancer; 3invasive carcinomas; 4in-situ carcinomas.
Figure 1 Graphical respesentation of a six-state parameter estimation model and a 10-state overdiagnosis model. This figure shows
states included in the parameter estimation model, a six-state Markov model of breast cancer progression for estimating screening parameters
including screening test sensitivity and mean sojourn time, and the overdiagnosis model, an extended 10-state model aimed at estimating the
extent of overdiagnosis. Dotted states are those added in the extension from the former to the latter model. The screen-detected in situ state
groups two distinct states: screen-detected progressive and non-progressive in situ.
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The intensity matrix, Q, for this model, with J, the
background incidence of invasive breast cancer, g, the
background incidence of in situ breast cancer, j, the
transition rate between PIS and PIBC, lis, the transition
rate between NPIS and CIS, and linv, the transition rate
between PIBC and CIBC was determined as
Q =
STATE
1 Healthy
2 NPIS
3 PIS
4 PIBC
5 CIBC
6 CIS
⎛
⎜⎜⎜⎜⎜⎜⎜⎜⎝
1 2 3 4 5 6
−(γ + J) γ J 0 0 0
0 −λis 0 0 0 λis
0 0 −φ φ 0 0
0 0 0 −λinv λinv 0
0 0 0 0 0 0
0 0 0 0 0 0
⎞
⎟⎟⎟⎟⎟⎟⎟⎟⎠
. (1)
Both J and g were obtained directly from the observed
age-specific incidence in the control arm of the Age
trial who were not offered any screening between the
ages of 40 to 49 years. Given the assumption of expo-
nential distribution of time to transition, the MST in a
state was the inverse of the transition rate. From the
intensity matrix, the probability of progression from any
state i to any state j in any time interval t, can be
defined as Pij (t). The derivation of transition probabil-
ities is based on the solution of Kolmogorov equations
and exponential distribution properties and will not be
developed here [11-13]. Given transition probabilities,
Pij (t), the probability of having a positive or negative
mammogram, as well as the incidence of breast cancer
in the interval between two screens can be formulated
(Table 2).
Women in this analysis were free from diagnosed
breast cancer at entry, meaning that, at the prevalent
screen, probabilities were conditional on being healthy or
in a preclinical disease state. The number of women
screened in each round, n.scrk, is given in Table 1. The
STS for in situ and invasive cancer were defined as Sis
and Sinv, respectively. In each screen, we defined the
probability of screen detection of NPIS, PIS, and PIBC.
The model was fitted to the observed number of in situ
and invasive cancers detected in each screen. For incident
screens, we defined the probability of having a false nega-
tive result in the previous screen for each preclinical can-
cer state. The monthly incidence of interval cancers was
defined for CIS and CIBC and fitted to the observed inci-
dence of in situ and invasive cancers, respectively, in the
first 12 months after each screen. This analysis was per-
formed using WinBUGS14. The median and 95% cred-
ible interval (CI) of the posterior distribution for each
Table 2 Probability of cancer detection at prevalent and incident screens, and monthly incidence of interval cancers.
Description Parameter Definition
Any screen k
Number of women screened n.scrk see Table 1
Negative screening episodes n.negk n.scrk(1− P.scrnpisk − P.scrpisk − P.scrinvk)
Proportion of false negatives at screen k
False negative NPIS P.fnegnpis
k
(P.scrnpiskn.scrk(1− Sis)/Sis)/n.negk
False negative PIS P.fnegpis
k
(P.scrpiskn.scrk(1− Sis)/Sis)/n.negk
False negative PIBC P.fneginvk (P.scrinvkn.scrk(1− Sinv)/Sinv)/n.negk
Any pre-cancer state P.fnegk P.fnegnpisk
+ P.fnegpis
k
+ P.fneginvk
Prevalent screen
Screen-detected NPIS P.scrnpis
1
SisP12(age)/(P11(age) + P12(age) + P13(age) + P14(age))
Screen-detected PIS P.scrpis
1
SisP13(age)/(P11(age) + P12(age) + P13(age) + P14(age))
Screen-detected PIBC P.scrinv1 SinvP14(age)/(P11(age) + P12(age) + P13(age) + P14(age))
Incident screen k
Screen-detected NPIS P.scrnpis
k
Sis
(
(1− P.fnegk−1)P12(t) + P.fnegnpisk−1P22(t)
)
Screen-detected PIS P.scrpis
k
Sis
(
(1− P.fnegk−1)P12(t) + P.fnegnpisk−1P22(t)
)
Screen-detected PIBC P.scrinvk Sinv
(
(1− P.fnegk−1)P14(t) + P.fnegpisk−1P34(t) + P.fneginvk−1P44(t)
)
Monthly incidence of interval cancers in the first m months after screen k
In-situ ICisk
n.negk(P11(m− 1)P16(1) + P12(m− 1)P26(1))
+P.scriskn.scrk(1− Sis)/Sis(P22(m− 1)P26(1))
Invasive ICinvk
n.negk(P11(m− 1)P15(1) + P13(m− 1)P35(1) + P14(m− 1)P45(1))
+P.scrinvkn.scrk(1− Sinv)/Sinv(P44(m− 1)P45(1))
+P.scrpiskn.scrk(1− Sis)/Sis(P34(m− 1)P45(1) + P33(m− 1)P35(1))
Age, age at first screen; NPIS, non-progressive in situ breast cancer; PIBC, preclinical invasive breast cancer; PIS, progressive in situ breast cancerl; t, screening
interval.
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parameter was obtained through Gibbs sampling, using 5
chains of 3000 iterations. Due to their correlated nature,
we also estimated the correlation between MST and STS.
Overdiagnosis model
The first model was extended to include 10 states in
order to estimate the absolute amount of overdiagnosis
due to screening (Figure 1). States included healthy, pre-
clinical NPIS, preclinical PIS, PIBC, screen-detected
NPIS, screen-detected PIS, CIS, screen-detected PIBC,
CIBC, and dead. In the simulation, 1,000,000 women
were followed up for 15 years in monthly cycles starting
from age 40. Transitions probabilities between states
were calculated using data from various sources: (1) the
Office for National Statistics (ONS), for the incidence of
invasive and in situ breast cancer [14] and all-cause death
rates [15] in women aged 40 to 54 from 2008, (2) the
Age trial [10], for the incidence of invasive and in situ
breast cancer in women aged 40 to 49, (3) the parameter
estimation model in this study, for the STS and MST in
pre-cancer states in women aged 40 to 49, and (4) esti-
mates from previous studies [7,8,11] for the MST in
women aged over 50. For the breast cancer incidence in
women aged 40 to 44, we used incidence rates reported
by ONS. For women aged 44 to 49, ONS incidence rates
are affected by screening at age 49; we therefore used the
incidence in the control arm of the Age trial, adjusted by
the ratio of the ONS rates to Age trial rates for the 40 to
44 age group. This resulted in higher incidence rates
than those observed in the Age trial control arm; it was
therefore not necessary to adjust these rates for selection
bias due to the lower observed rate in non-attenders. For
the base-case analysis, the medians of our MST and STS
estimates were used. We also performed sensitivity ana-
lyses to investigate the impact of changing MST and STS
on the estimate of overdiagnosis. We considered the fol-
lowing scenarios: high MST, low MST, high STS, low
STS, high MST with low STS, and high MST with high
STS (Table 3). This analysis was performed using Tree-
Age Pro 2011 (TreeAge Software Inc., Williamstown,
MA, USA).
Results
Estimates from the parameter estimation model are shown
in Table 4. The median and 95% CI for the invasive and in
situ mammography STS were 90.0% (72.0 to 98.9) and
81.7% (43.4 to 99.0), respectively. Model estimates for the
MST in the screen-detectable PIBC state was 0.84 years
(0.64 to 1.21), which, added to the MST in the screen-
detectable PIS state, 0.11 years (0.05 to 0.19), gave a mean
window of 0.95 years for a cancer to be detected via
screening before arising clinically. For screen-detectable
NPIS, the MST was 1.29 years (0.41 to 3.44). The esti-
mated proportion of screen-detected in situ cancers that
were non-progressive was 55% (25-77) in the prevalent
and 40% (22 to 60) in incident screens.
Results of the overdiagnosis model are given in Table 5.
In our base-case analysis, 16,030 breast cancers were
diagnosed between the ages of 40 and 49 years in women
offered screening, in contrast with 15,425 in women not
offered any screening, a surplus of 605 cases, equivalent
to 6.2% of screen-detected and 3.8% of all cases. How-
ever, in ages 50 to 54, where screening is not offered in
both simlulated groups, 541 additional cases were diag-
nosed in women not offered screening previously, result-
ing in a total of 64 overdiagnosed cases equivalent to
0.7% of screen-detected cases and 0.4% of all cancers
diagnosed within ages 40 to 49 years.
Estimates of overdiagnosis in our sensitivity analysis
ranged from 0.5 to 2.9% of screen-detected cancers and
0.3% to 2.2% of all cancers diagnosed within ages 40 to
49 years. The highest impact on overdiagnosis was
observed when increasing the MST, whereas increasing
the STS had a smaller impact on overdiagnosis (Table 6).
Table 3 Parameter definitions for base-case and sensitivity analyses of overdiagnosis model.
Screening test Mean sojourn time (years)
sensitivity (%) 40 to 49 50-59
Invasive Invasive In-situ NPIS PIS PIBC NPIS PIS PIBC
Base case Median1 Median 3 0.175 1.825
Long MST Median Upper limit2 5 0.25 2.75
Short MST Median Lower limit3 2 0.1 1.5
High sensitivity 100 100 Median 3 0.175 1.825
Low sensitivity Lower limit Median 3 0.175 1.825
Low sensitivity, long MST Lower limit Upper limit 5 0.25 2.75
High sensitivity, long MST 100 100 Upper limit 5 0.25 2.75
1,2,3Refers to the median, upper limit, and lower limit of results from parameter estimation model, respectively. MST, median sojourn time; NPIC, non-progressive
in situ; PIBC, preclinical invasive breast cancer; PIS, preclinical progressive in situ.
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Model fit
When compared to data from the Age trial, the para-
meter estimation model accurately predicted the screen-
detected invasive cancers for the first six screens, but
underestimated those for the last two screens (Table 7).
For screen-detected in situ cancers, model predictions
were accurate for the first five screens, but underesti-
mated the observed number for the last three screens.
The number of invasive interval cancers were overesti-
mated for the first screen, and underestimated in the
last three screens. The expected number of in situ inter-
val cancers were underestimated for the last screen only.
For all screens combined, the model slightly underesti-
mated the number of screen-detected invasive cancers.
Expected values from the overdiagnosis models were
within the range of estimates from the parameter
Table 4 Model estimates of breast cancer screening and
progression parameters in women aged 40 to 49 years
Parameter Estimate
Median 95% CI
Screening test sensitivity (%)
Invasive 90.0 (72.0-98.9)
In-situ 81.7 (43.4-99.0)
Mean sojourn time (years)
Invasive 0.84 (0.64-1.21)
Progressive in situ 0.11 (0.05-0.19)
Non-progressive in situ 1.29 (0.41-3.44)
% of screen-detected in situ that is non-progressive
Prevalent screen 55 (25-77)
Incident screens 40 (22-60)
Table 5 Comparison of the number of cancers detected for 1,000,000 women in annual screening between ages 40 to
49 years versus no screening versus.
Ages 40 to 49 Ages 50 to 54 Ages 40 to 54
Group 1 Annual
screening
Group 2 No
screening
Group 1 No
screening
Group 2 No
screening
Group 1
Total
Group 2
Total
Base-case
Screen-detected
Invasive 7772 - - - 7772 -
Progressive in situ 1145 - - - 1145 -
Non-progressive in situ 874 - - - 874 -
Clinically detected
Invasive 5693 14 089 7680 8151 13 373 22 240
Non-progressive in situ 546 1336 658 728 1204 2064
All cancers 16 030 15 425 8338 8879 24 368 24 304
Overdiagnosis
Absolute number 605 -541 64
% of screen-detected 6.2 0.7
% of cancers diagnosed within
ages 40 to 49
3.8 0.4
Estimates from the overdiagnosis model.
Table 6 Overdiagnosis of breast cancer due to annual screening in women aged 40 to 49 years.
Overdiagnosis
Scenario % of screen-detected % diagnosed within ages 40 to 49
Base-case 0.7 0.4
Long MST 2.7 2.0
Short MST 0.5 0.3
High sensitivity 0.7 0.4
Low sensitivity 0.5 0.3
High sensitivity, long MST 2.9 2.2
Low sensitivity, long MST 2.7 1.6
Results of sensitivity analysis. Overdiagnosis
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estimation model, and had a similar fit to the observed
data in the intervention arm. The fit of the expected
numbers of cancers in the control arm was good, with a
slight overprediction overall of approximately 2%.
Discussion
In this study, we aimed to quantify the overdiagnosis of
breast cancer attributable to screening women aged 40 to
49 years annually by first estimating screening parameters
in a six-state Markov model using data from a trial of
annual mammographic screening starting age 40 con-
ducted in the UK. In women aged 40 to 49 years in the
UK, we estimated that only 0.3% to 2.2% of all cancers
were overdiagnosed.
An implicit assumption of the Markov process is that
the time to transition is distributed exponentially. This dis-
tribution has been used in many instances previously and
has been shown to have a good fit to progression models
Table 7 Fit of model estimates to data observed in a trial of annual mammographic screening starting age 40 in the
UK.
Invasive In-situ
Observed Expected Observed Expected
Screening
episode
AGE trial Paremeter estimation
model
Overdiagnosis
model
AGE trial Paremeter estimation
model
Overdiagnosis
model
Intervention arm (offered annual screening)
Screen-detected cancers
1 31 28(22-34) 32 6 7(3-12) 7
2 20 18(16-20) 19 3 5(2-8) 5
3 16 17(15-19) 18 3 5(2-7) 5
4 15 17(15-18) 17 5 5(2-6) 5
5 16 15(13-17) 16 4 5(2-6) 4
6 13 14(13-15) 15 7 3(2-6) 4
7 19 14(12-15) 14 9 3(2-6) 4
8 21 11(10-12) 12 6 3(2-4) 3
Total 151 134(116-150) 143 43 36(17-55) 37
Interval cancers
1 7 19(16-23) 16 2 1.4(0.6-2.6) 2
2 17 17(14-19) 14 2 1.3(0.5-2.4) 1
3 17 15(13-18) 13 0 1.2(0.5-2.2) 1
4 17 13(11-15) 13 1 1(0.4-1.9) 1
5 10 12(10-14) 12 0 0.9(0.4-1.7) 1
6 16 12(10-13) 11 1 0.9(0.4-1.7) 1
7 18 10(8-11) 11 1 0.7(0.3-1.4) 1
8 11 4(3-5) 9 2 0.2(0.1-0.5) 1
Total 113 102(85-118) 99 9 7.6(3.2-14.4) 9
Control arm (not offered screening)
40 52 -1 69 1 - 5
41 115 - 111 8 - 7
42 115 - 124 7 - 9
43 129 - 133 7 - 12
44 138 - 147 15 - 13
45 161 - 155 16 - 12
46 161 - 160 12 - 10
47 165 - 165 7 - 11
48 172 - 166 13 - 12
Total 1208 - 1230 86 - 91
1The parameter estimation model was built using the incidence in the control arm.
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for breast cancer, as well as other cancers [11,12,16]. We
assumed that all in situ cancers that arose in the absence
of screening were non-progressive. In reality, a proportion
of in situ cases detected in the absence of screening may
be progressive. However, this proportion could not be esti-
mated when relaxing this assumption.
Estimates from our overdiagnosis model suggest a 5%
reduction in the detection of invasive cancers as a result of
screening. Previously, three screening trials (the Two-
County, Stockholm, and Goteborg trials) showed a
non-significant reduction of 5% to 10% in the incidence of
invasive breast cancer when comparing the incidence in
the screened and control groups [17]. Also, we assumed
that all invasive cancers had an in situ precursor, which
may not be the case [18]. Hence, our model may have
overestimated the number of invasive cancers detected in
their in situ precursor state. However, it is unlikely that
this would affect our estimates of overdiagnosis as both in
situ and invasive breast cancers were included in our
calculations.
Our results showed that the STS for in situ cancers was
approximately 10% lower than for invasive cancers, prob-
ably due to the larger size of invasive tumours [19].
Although no previous studies estimated the STS of in
situ cancers separately, previous estimates of the STS for
preclinical breast cancer ranged from 69% to 100%
[6-8,13], consistent with our 90% STS estimate for PIBC.
In the Age trial, two-view mammograms were performed
at prevalence screen, and one-view at incident screens
unless indicated otherwise. When estimated separately,
we found a 10% difference in prevalent (95%, 79 to 100)
and incident STS (85%, 69 to 95). However, this model
did not show any improvement in fit, and could not esti-
mate the difference in STS for in situ and invasive breast
cancer, which are more important parameters with
regards to overdiagnosis due to screening. In addition,
the STS of mammography is likely to increase with
increasing age [9]; it was not possible to incorporate this
in the current model, but our sensitivity analysis found
that increasing the sensitivity had limited impact on the
estimate of overdiagnosis. Estimates of MST and STS are
necessarily related. The correlation between STS and
MST in our model was 0.75 and their distribution
showed no sign of bimodality. The sensitivity analysis
addressed the correlated nature of STS and MST, by the
inclusion of a scenario with long MST and small STS as
an alternative to our base-case model, which had short
MST and high STS.
The MST for screen-detectable NPIS was the longest
among pre-cancer states, suggesting that more NPIS are
detected in the prevalent screen than in incident
screens. For screen-detectable PIS, the MST was very
short, roughly three to ten weeks. Being much shorter
than the yearly screening interval, this implies that few
progressive lesions are detected in the in situ stage.
However, the pool of progressive lesions will renew itself
at each screen, implying that the rate of progressive
lesions detected at each screen is constant proportion-
ally to the background incidence of invasive breast can-
cer. According to our estimates, the combined MST of
PIS and PIBC was under one year in 66% of cases. This
would support annual screening for women aged 40 to
49. Biennial or triennial screening would result in many
women developing both pre-cancer and having a clinical
diagnosis during the screening interval.
To our knowledge, only one study used a six-state
Markov model to estimate the detection rates of NPIS in
screening, but did not estimate STS [11]. Using UK data
for women aged 50 and over, authors predicted that 39%
and 21% of screen-detected in situ cancers were non-pro-
gressive at prevalent and incident screens, respectively.
The model had a lack of fit for UK data, overestimating
cancers detected at prevalent and underestimating
cancers detected at incident screens. In this study, we
predicted a higher proportion of NPIS, possibly due to a
higher relative background incidence of in situ to invasive
cancer in women aged 40 to 49 compared to women
aged 50 to 69 [14]. In previous studies, the MST of PIBC
in women aged 40 to 49 ranged from 1.05 to 2.46 years
[6-8,13,20], which is longer than our estimate of 0.95
years. However, this study is the first to report MST esti-
mates for women aged 40 to 49 in the UK, and for older
women, previous estimates show a shorter MST in
British women compared to other European countries
[11].
Our estimate of overdiagnosis for annual screening in
women aged 40 to 49 in the UK was in line with those
reported in other studies. Hellquist et al. [21] estimated
that 1% (-6 to 8) of all breast cancers were overdiagnosed
in a screening programme for women aged 40 to 49
screened every 18 months in Sweden. In a systematic
review, the range of overdiagnosis for women aged 40 to
49 years was -4% to 7.1% [22]. Despite large credible inter-
vals in our estimates of STS and MST, the range of over-
diagnosis from this study was small, 0.3% to 2.2% of breast
cancers diagnosed within ages 40 to 49 years. Thus,
although precise estimates of STS and MST are hard to
obtain, the estimate of overdiagnosis is relatively unaected.
Our sensitivity analysis included a large range of STS and
MST values, and our results should be generalisable to
other countries with similar breast cancer incidence rates
as the UK. However, it is not clear to what extent our
results are extendable to programmes with longer screen-
ing intervals: the impact of screening frequency on over-
diagnosis in women aged 40 to 49 years would require
further studies.
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Conclusions
The most important implication of this study is that, in
women aged 40 to 49 in the UK, a small proportion of
breast cancers were overdiagnosed due to screening,
between 0.3% to 2.2% of all breast cancers diagnosed
within ages 40 to 49 years. Since women aged 40 to 49
have shorter MST, lower STS, and lower mortality rates
than women aged 50 and over, less overdiagnosis would
normally be expected which may explain why estimates of
overdiagnosis from this study are smaller than those
reported for women aged 50 onwards [2,3,23,24]. Second,
although a high proportion of in situ cancers detected at
screening were estimated to be non-progressive, the great
majority of these would have presented clinically in the
absence of screening, implying they would not be over-
diagnosed. Finally, the mean sojourn time of preclinical
invasive breast cancer, including its in situ precursor, was
just under one year, suggesting that annual screening
would be most appropriate for women aged 40 to 49.
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